Cognitive Longevity
Making brain health screening as routine and accessible as any other essential health check
We combine patented intracellular multi-omics analytics using DNA Nanoprobes, Proteomics, and AI to uncover novel pathways for Neurodegenerative diseases
We combine patented intracellular analytics using DNA nanoprobes with AI to diagnose neurodegenerative diseases before symptoms manifest.
We use patented DNA nanotechnology
A paradigm shift in understanding how Alzheimer’s and Parkinson’s diseases manifests opens up a whole new way of diagnosing, treating and managing the disease.
Advanced Probes by Esya
Multi-Omics Data Analysis Platform
Our Expertise & Capabilities
Regulated Biomarker Validation
We adhere to GLP & CLIA standards to ensure biomarker assays meet the highest quality for preclinical and clinical research.
Custom Assay Development
We design high-sensitivity biomarker platforms tailored for biopharma, biotech, and clinical research applications.
Advanced Bioinformatics & AI
By harnessing machine learning and AI-driven analytics, we enhance biomarker discovery and accelerate drug developmemt.
Multi-Omic Discovery
By integrating genomics, proteomics, and live-cell imaging, we identify disease signatures and stratify patients with precision.
Scalable Clinical Trial Support
With high-throughput biomarker platforms, we optimize large-scale sample processing to meet clinical trial demands.
Strategic Industry Partnership
Through our collaboration with Alamar Biosciences, we offer ultra-sensitive NULISA assays, including CN120 & 250 Neuroinflammation panels for CNS and inflammatory diseases.
Neurodegenerative Disease Focus
Our expertise in Alzheimer’s, Parkinson’s, and CNS disorders leverages lysosomal biology and AI-driven biomarker detection.
A whole new way of discovering novel pathways for Brain health
Voltair
DNA-based sensor for absolute membrane potential of cell and organelle membranes. Relevant to various neurological diseases, hypokalemia, or hyperkalemia
CalipHluor
DNA-based, ratiometric combination reporter of pH and Ca2+. Relevant to Alzheimer’s disease, Pakinson's disease and Kufor Rakeb syndrome.
Clensor
pH-independent, ratiometric Cl- sensor, single colour, multiplexing enabled. Relevant to Lysosomal storage disorders and Niemann Pick.
NOckout
DNA-based ratiometric NO sensitive probes. Relevant to cancer, autoimmune disease, sepsis and trauma, and vascular disease.
Accelerate Drug Development
Our ratio-metric assays and multiplexed proteomic panels are exceptional in their ability to quantify the key chemicals within endosomes (early, recycling, and late), lysosomes, and the golgi. They can be used to complement drug discovery and patient stratification, as well as assess drug efficacy as an end point in clinical trials for lysosomal storage disorders and numerous neurocognitive impairments.